• Weijia Li, Saul Rios, Sanjana Nagraj, Adrija Hajra, Tinatin Saralidze, Dimitrios Varrias, Sheetal Vasundara Mathai, Marko Novakovic, Kenneth H Hupart, Jeremy A Miles, Adarsh Katamreddy, Leonidas Palaiodimos, and Robert T Faillace.
• Department of Medicine, New York City Health + Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.
• Am. J. Med. 2022 Jul 1; 135 (7): 897-905.

IntroductionStatins have been commonly used for primary and secondary cardiovascular prevention. We hypothesized that statins may improve in-hospital outcomes for hospitalized patients with Coronavirus disease 2019 (COVID-19) due to its known anti-inflammatory effects.MethodsWe conducted a retrospective study at the largest municipal health care system in the United States, including adult patients who were hospitalized for COVID-19 between March 1 and December 1, 2020. The primary endpoint was in-hospital death. Propensity score matching was conducted to balance possible confounding variables between patients receiving statins during hospitalization (statin group) and those not receiving statins (non-statin group). Multivariate logistic regression was used to evaluate the association of statin use and other variables with in-hospital outcomes.ResultsThere were 8897 patients eligible for study enrollment, with 3359 patients in the statin group and 5538 patients in the non-statin group. After propensity score matching, both the statin and non-statin groups included 2817 patients. Multivariate logistic regression analysis showed that the statin group had a significantly lower risk of in-hospital mortality (odds ratio 0.71; 95% confidence interval, 0.63-0.80; P < .001) and mechanical ventilation (OR 0.80; 95% confidence interval, 0.71-0.90; P < .001) compared with the non-statin group.ConclusionStatin use was associated with lower likelihood of in-hospital mortality and invasive mechanical ventilation in hospitalized patients with COVID-19.Copyright © 2022 Elsevier Inc. All rights reserved.

14 keywords...

hide…